CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents

Saved in:
Bibliographic Details
Published inBlood Vol. 140; no. Supplement 1; p. 11575
Main Authors Perino, Samantha, Kirby, R. Jason, Agafonov, Roman, Chaturvedi, Prasoon, Eron, Scott, Good, Andrew, Hart, Ashley, He, Minsheng, Lobbardi, Riadh, Phillips, Andrew J, Proia, David, Henderson, James, Thomeius, Michael, Nasveschuk, Christopher, Fisher, Stewart L, Pollock, Roy Macfarlane
Format Journal Article
LanguageEnglish
Published Elsevier Inc 15.11.2022
Online AccessGet full text
ISSN0006-4971
1528-0020
DOI10.1182/blood-2022-166541

Cover

Author Chaturvedi, Prasoon
Phillips, Andrew J
Thomeius, Michael
Fisher, Stewart L
Henderson, James
He, Minsheng
Agafonov, Roman
Proia, David
Pollock, Roy Macfarlane
Kirby, R. Jason
Eron, Scott
Lobbardi, Riadh
Nasveschuk, Christopher
Hart, Ashley
Good, Andrew
Perino, Samantha
Author_xml – sequence: 1
  givenname: Samantha
  surname: Perino
  fullname: Perino, Samantha
  organization: C4 Therapeutics, Watertown, MA
– sequence: 2
  givenname: R. Jason
  surname: Kirby
  fullname: Kirby, R. Jason
  organization: C4 Therapeutics, Watertown, MA
– sequence: 3
  givenname: Roman
  surname: Agafonov
  fullname: Agafonov, Roman
  organization: C4 Therapeutics, Watertown, MA
– sequence: 4
  givenname: Prasoon
  surname: Chaturvedi
  fullname: Chaturvedi, Prasoon
  organization: C4 Therapeutics, Watertown, MA
– sequence: 5
  givenname: Scott
  surname: Eron
  fullname: Eron, Scott
  organization: C4 Therapeutics, Watertown, MA
– sequence: 6
  givenname: Andrew
  surname: Good
  fullname: Good, Andrew
  organization: C4 Therapeutics, Watertown, MA
– sequence: 7
  givenname: Ashley
  surname: Hart
  fullname: Hart, Ashley
  organization: C4 Therapeutics, Watertown, MA
– sequence: 8
  givenname: Minsheng
  surname: He
  fullname: He, Minsheng
  organization: C4 Therapeutics, Watertown, MA
– sequence: 9
  givenname: Riadh
  surname: Lobbardi
  fullname: Lobbardi, Riadh
  organization: C4 Therapeutics, Watertown, MA
– sequence: 10
  givenname: Andrew J
  surname: Phillips
  fullname: Phillips, Andrew J
  organization: C4 Therapeutics, Watertown, MA
– sequence: 11
  givenname: David
  surname: Proia
  fullname: Proia, David
  organization: C4 Therapeutics, Watertown, MA
– sequence: 12
  givenname: James
  surname: Henderson
  fullname: Henderson, James
  organization: C4 Therapeutics, Watertown, MA
– sequence: 13
  givenname: Michael
  surname: Thomeius
  fullname: Thomeius, Michael
  organization: C4 Therapeutics, Watertown, MA
– sequence: 14
  givenname: Christopher
  surname: Nasveschuk
  fullname: Nasveschuk, Christopher
  organization: C4 Therapeutics, Watertown, MA
– sequence: 15
  givenname: Stewart L
  surname: Fisher
  fullname: Fisher, Stewart L
  organization: C4 Therapeutics, Watertown, MA
– sequence: 16
  givenname: Roy Macfarlane
  surname: Pollock
  fullname: Pollock, Roy Macfarlane
  organization: C4 Therapeutics, Watertown, MA
BookMark eNp9kE2P0zAQQC20SHQXfgA337isWY_jpI44RYGyK8qHRE9cIn9MuobErmxT1L_FLySlnDnNXN6b0bsmVyEGJOQl8NcAStyZKUbHBBeCQdPUEp6QFdRCMc4FvyIrznnDZLuGZ-Q65--cg6xEvSK_-81uLev6lmr6KR5xog8fvm3grqJvcZ-0w3S7bHMMuSRdMNMvsWAotAvFs93POSba2eKPvpyoD_RjdDhlGsdFFth9dPsfPrzKdHuaD49x1rTLy6GvPuwnpN3-bFoMC9jH2figi4-B_vLlkfaTD97qaTrR7nBIy2vuAuTn5Omop4wv_s0bstu82_X3bPv5_UPfbZltJTClnFVKrRsjBKpa26YCtLJplYHKQOPQwBrAgDGjUKMEzUXbgpWqwtrIqrohcNHaFHNOOA6H5GedTgPw4dx8-Nt8ODcfLs0X5s2FWSLg0WMasvUYLDqf0JbBRf8f-g_6gItf
ContentType Journal Article
Copyright 2022 The American Society of Hematology
Copyright_xml – notice: 2022 The American Society of Hematology
DBID AAYXX
CITATION
DOI 10.1182/blood-2022-166541
DatabaseName CrossRef
DatabaseTitle CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Biology
Anatomy & Physiology
EISSN 1528-0020
EndPage 11575
ExternalDocumentID 10_1182_blood_2022_166541
S0006497122068173
GroupedDBID ---
-~X
.55
1CY
23N
2WC
34G
39C
4.4
53G
5GY
5RE
5VS
6J9
AAEDW
AAXUO
ABOCM
ABVKL
ACGFO
ADBBV
AENEX
AFOSN
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BTFSW
CS3
DIK
DU5
E3Z
EBS
EJD
EX3
F5P
FDB
FRP
GS5
GX1
IH2
K-O
KQ8
L7B
LSO
MJL
N9A
OK1
P2P
R.V
RHF
RHI
ROL
SJN
THE
TR2
TWZ
W2D
W8F
WH7
WOQ
WOW
X7M
YHG
YKV
ZA5
0R~
AALRI
AAYXX
ACVFH
ADCNI
ADVLN
AEUPX
AFETI
AFPUW
AGCQF
AIGII
AITUG
AKBMS
AKRWK
AKYEP
CITATION
H13
ID FETCH-LOGICAL-c941-88dc88876b22e85ac631ec4698b13b16deb1711b1bbf28f41a02991c483e5b433
ISSN 0006-4971
IngestDate Tue Jul 01 04:29:55 EDT 2025
Fri Feb 23 02:36:05 EST 2024
IsPeerReviewed true
IsScholarly true
Issue Supplement 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c941-88dc88876b22e85ac631ec4698b13b16deb1711b1bbf28f41a02991c483e5b433
PageCount 1
ParticipantIDs crossref_primary_10_1182_blood_2022_166541
elsevier_sciencedirect_doi_10_1182_blood_2022_166541
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-11-15
PublicationDateYYYYMMDD 2022-11-15
PublicationDate_xml – month: 11
  year: 2022
  text: 2022-11-15
  day: 15
PublicationDecade 2020
PublicationTitle Blood
PublicationYear 2022
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
SSID ssj0014325
Score 2.410823
SourceID crossref
elsevier
SourceType Index Database
Publisher
StartPage 11575
Title CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents
URI https://dx.doi.org/10.1182/blood-2022-166541
Volume 140
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbtNAEF2FIi4vCFIQ5aZ9QCDhus36nkcTiEJLo0KDVPFi7XrXaaTYRnZSKXwWn8IXMXtxnKhFgr5YjpXJrnROZma9Z2cQek0oyWQksXnqc9ujvGdHnMLCtR_I0i6EsFSeHT4ZB6Nv3tG5f97p_N5QLS0X7CD9ee25kpugCs8AV3lK9j-QXf8oPIB7wBeugDBc_wnjwXASer6vFJjWuLwUc-vT8fehdE4ueJJpRblG5IPIZR4oy0LU1mm5kAKAuFjM7MkyL6VI3vSQmBWqOZquqDwuC3tU8qlq2BXW1ucVIF_mFCCF4c4g5s2FFU-VmKDSpwdzWGdrRqn3u6bo6Hy-ktluBRPk2qDe2kuem4b12kVXM9UN3DqjOaB-sQ4bx7NKVwH9emAd0bqVD8RTmpVFeamF4nlL98GFrFoKgyrFwmkFRsbKvOaAFbKU2vntu7fm_M2WPFQGW9kjT7NTGBcua273nN6Wj9c1oYyXliz0N0L--vPVeBLJ-rT6DIGelezWTNrguZY0nqnsDqbiOL0gIqF7C912QsjnpFDgS7uz5bmO7qphZm522mGgwyvDXJ8rbeQ_k4fogVm44Fiz8BHqiKKLdmOAu8xX-A1WUmK1R9NFd943d_cGTUPBLrp7YnQcu-iXYe4-pljxFiveHrq4Ye0-3uQs1pzFLWdxw1k8K7DmLC4zvMHZtzVuGIvjGgbSjMWKgBh-AQw3GIslY3HLWNwwVhvUj9Fk-HEyGNmme4id9j1iRxFPI4igAXMcEfk0DVwiUtkvlRGXkYBDkiJdEWEsc6LMI7QHmRlJvcgVPvNc9wnaKcpCPEVYeP1MwDqCZ0J-T1BGgz4LAz_kTHAv2kPvGpiSH7pGTKLW1pGTKEwTiWmiMd1DXgNkYpJcnbwmwLm_mz27mdlzdL_9M71AO4tqKV5CFr1grxQt_wAER8Vi
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=CFT7455%2C+a+Novel+IKZF1%2F3+Degrader%2C+Demonstrates+Potent+Anti-Tumor+Activity+in+Models+of+Non-Hodgkin%27s+Lymphoma+As+a+Single+Agent+or+in+Combination+with+Clinically+Approved+Agents&rft.jtitle=Blood&rft.au=Perino%2C+Samantha&rft.au=Kirby%2C+R.+Jason&rft.au=Agafonov%2C+Roman&rft.au=Chaturvedi%2C+Prasoon&rft.date=2022-11-15&rft.pub=Elsevier+Inc&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=140&rft.spage=11575&rft.epage=11575&rft_id=info:doi/10.1182%2Fblood-2022-166541&rft.externalDocID=S0006497122068173
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon